Shire Could Get More Out Of OPUS-3 Than Refiling Lifitegrast
This article was originally published in Scrip
Executive Summary
In addition to supporting resubmission of the new drug application (NDA) for Shire PLC's dry-eye disease candidate lifitegrast, the specialty pharma is emphasizing that the just-completed OPUS-3 trial shows that lifitegrast is the first drug ever to demonstrate symptom improvement over consecutive trials in dry eye.
You may also be interested in...
Shire's Xiidra Gets Advantageous Label Covering Signs, Symptoms Of Dry Eye Disease
By examining the "totality of the data" including a Phase II study, FDA approved drug for both measures of dry eye, despite mixed results in pivotal trials.
Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger
Shire's Danish chief executive says completing the Baxalta merger will greatly boost the group's exposure to longer acting orphan drugs, bring critical mass and de-risk its current asset mix with new portfolio products; a view widely shared by investors and analysts.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.